Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million that had been brought by 2,625 people living with HIV.

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday, sending ...

Lenacapavir approved for PrEP in EU, Norway, Iceland, Liechtenstein Pricing, reimbursement to be determined with each country Gilead's lenacapavir nearly 100% effective in trials Aug 26 (Reuters) - ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Gilead's HIV franchise remains dominant, generating $19.612 billion in 2024, but faces potential funding challenges impacting future growth. Efforts to build a cancer franchise have been mixed; ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...

Gilead delivered a mixed fourth quarter relative to expectations. The biopharma giant also issued underwhelming forward guidance. Gilead's fourth-quarter 2023 revenue declined 3.7% year over year to ...